Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

Prior treatment

• Having previously received surgical treatment, pelvic radiotherapy, systemic chemotherapy, tumor targeted therapy, or immunotherapy for cervical cancer.
• Active infectious processes necessitating antimicrobial therapy, including the use of antibacterial, antiviral, or antifungal agents.
• Unable to receive intracavitary radiotherapy.

Other illness

• With rectovaginal fistula/vaginal vesical fistula/uncontrolled massive vaginal bleeding or at risk of developing a fistula.
• History of immunodeficiency, including HIV seropositivity or other acquired and congenital immunodeficiency disorders.
• History of other malignant tumors (except for cured basal cell carcinoma of the skin).
• Crohn's disease or ulcerative colitis.
• Allergic to nimotuzumab or its components.
• Neurological or mental disorders affecting cognitive ability.

Lab values

• Uncontrolled cardiac symptoms or diseases, such as NYHA class II or higher heart failure, unstable angina, myocardial infarction within the past year, atrial fibrillation, clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention, PR interval greater than 250 ms, or QTc interval ≥470 ms.

Other

• Cervical adenocarcinoma and other rare pathological types.
• Bilateral hydronephrosis, unless resolved by unilateral stent placement or percutaneous nephrostomy, or deemed mild and without clinical significance by the investigator.
• Pregnant women or those in the lactation period.
• contraindications for cisplatin use.
• Other reasons not suitable for participating in this study.

• Aged between 18 and 75 years old.
• Newly diagnosed cervical squamous cell carcinoma confirmed by histology, with a clinical stage of stage III - IVA (FIGO 2018 staging).
• No prior receipt of surgery, radiotherapy, or systemic anticancer therapy for the treatment of cervical cancer.
• No previous exposure to the study drug.
• Presence of at least one measurable or evaluable lesion as per RECIST version 1.1, with the measurable lesion exhibiting a longest diameter of ≥10 mm on spiral CT scan or a shortest diameter of ≥15 mm for enlarged lymph nodes, which has not been previously irradiated.
• Absence of central nervous system diseases, both primary and metastatic.
• WHO/ECOG performance status score of 0-1.
• Anticipated survival duration of at least 12 weeks.
• Adequate organ function within the following parameters (without the use of any blood components, cytokines, or growth factors within 14 days prior to randomization):
  • Absolute neutrophil count (ANC) ≥1.5×10\^9/L
  • Platelet count ≥90×10\^9/L
  • Hemoglobin level ≥90 g/L
  • Serum albumin level ≥30 g/L
  • Bilirubin level ≤1.5 times the upper limit of normal (ULN)
  • Alanine transaminase (ALT) and aspartate transaminase (AST) levels ≤3×ULN
  • Serum creatinine level ≤1.5×ULN
  • Thyroid-stimulating hormone (TSH) level ≤1×ULN (with eligibility also extended to patients with free triiodothyronine \[FT3\] or free thyroxine \[FT4\] levels ≤1×ULN).
• For women of childbearing potential not undergoing surgical sterilization, a negative serum pregnancy test (hCG) within 72 hours prior to study randomization is required; breastfeeding must be absent. Additionally, the use of a medically approved contraceptive method is mandatory from the time of informed consent through the study treatment period and for 120 days following the final administration of the trial medication or 180 days after the last chemotherapy/ radiotherapy session. Participants must also agree not to donate eggs for reproductive purposes or to freeze/preserve eggs for this use during the aforementioned period.
• Informed consent must be obtained with documentation.
• Availability for follow-up assessments.